GM101 / Genemagic Biosciences - LARVOL DELTA

First-in-Human Evaluation of an AAV Gene Therapy Enabling Astrocyte-to-Neuron Conversion for Neurorestoration in Parkinson’s Disease (ASGCT 2026) - P1 | "The concordance of clinical effects with increased DAT binding provides preliminary biological support for a neurorestorative mechanism. Ongoing enrollment in higher dose levels and longer follow-up will further define the safety profile, durability of effect, and biomarker correlates of GM101, informing the continued clinical development of AtN conversion gene therapy for PD."

First-in-human • Gene therapy • Neurorestoration • P1 data • CNS Disorders • Depression • Gene Therapies • Geriatric Disorders • Movement Disorders • Parkinson's Disease